Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association
Heart Failure in the Era of Precision Medicine: A Scientific Statement From the American Heart Association
复制标题
DOI：
10.1161/hcg.0000000000000058
复制
发表时间：
2019-10-01
影响因子：
7.4
通讯作者：
Wolf, Matthew J.
中科院分区：
文献类型：
--
作者：
Cresci, Sharon;Pereira, Naveen L.;Wolf, Matthew J.
每5个人中就有一个会在他或她的一生中患上心力衰竭。早期诊断和更好地了解该病的病理生理机制是最佳治疗的关键。心力衰竭的“组学”--基因组学、药物基因组学、表观基因组学、蛋白质组学、代谢组学和微生物学--代表着迅速扩展的科学领域，到目前为止，这些领域还没有整合到一个单一的工作体系中。这份声明的目的是全面概述这些组学与心力衰竭的发展和进展有关的现状，并考虑这些数据在预防、诊断和治疗方面的当前和潜在的未来应用。
One of 5 people will develop heart failure over his or her lifetime. Early diagnosis and better understanding of the pathophysiology of this disease are critical to optimal treatment. The "omics"-genomics, pharmacogenomics, epigenomics, proteomics, metabolomics, and microbiomics- of heart failure represent rapidly expanding fields of science that have, to date, not been integrated into a single body of work. The goals of this statement are to provide a comprehensive overview of the current state of these omics as they relate to the development and progression of heart failure and to consider the current and potential future applications of these data for precision medicine with respect to prevention, diagnosis, and therapy.